Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (abbreviated as “Biocytogen”) disclosed its Monthly Return for Equity Issuer for the period ended 30 September 2026. Key take-aways are as follows:
Authorised / Registered Share Capital • Total authorised share capital stood unchanged at RMB 446.90 million, split between 110.78 million H-shares and 336.12 million A-shares, each with a par value of RMB 1. • No new authorisations, cancellations or other adjustments were recorded during the month.
Issued Shares and Treasury Shares • Issued H-shares remained at 110.78 million; issued A-shares stayed at 336.12 million. • The company held zero treasury shares across both share classes, and no share repurchases or cancellations took place.
Public Float Compliance • Biocytogen confirmed compliance with the Hong Kong Stock Exchange’s minimum 5% public-float requirement for PRC issuers with other listed shares.
Corporate Actions • The company reported no activity under share option schemes, warrants, convertible securities, or other equity-linked arrangements for September 2026.
Governance • The monthly return was submitted on 5 October 2026 by Joint Company Secretary Mr Wang Yongliang, indicating adherence to ongoing disclosure obligations.
Overall, Biocytogen’s share capital structure and public-float status remained stable throughout September 2026, with no equity issuance, repurchase, or capital adjustment events reported.
Comments